Overview

Dermira is a medical dermatology company committed to bringing science and innovation to patients.

Innovation and product development in the field of medical dermatology has lagged behind other disease areas and, until recently, most companies in the space have primarily focused on reformulations of existing treatments. While there have been significant treatment developments for a limited number of conditions such as psoriasis and more recently atopic dermatitis, the standard of care for most dermatologic conditions has not changed in several decades.

As a result, new treatment options for dermatologic conditions are needed to help address the needs of, and deliver value to, patients and healthcare professionals.

We are re-envisioning medical dermatology.

Dermira is dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.

We have a unique portfolio of four product candidates to treat the following conditions: primary axillary hyperhidrosis (excessive sweating), moderate-to-severe chronic plaque psoriasis, acne vulgaris and moderate-to-severe atopic dermatitis. These candidates could have a profound impact on the lives of patients living with these chronic skin conditions.

We aim to serve patient needs across the $21 billion medical dermatology market by going beyond incremental improvements and focusing on developing game-changing therapies that will elevate existing standards of care for people living with chronic skin diseases.

Primary Axillary Hyperhidrosis

We are developing glycopyrronium tosylate (formerly DRM04), an anticholinergic agent formulated for topical administration, for primary axillary hyperhidrosis, excessive sweating of the underarms that causes emotional, social and physical impairment and affects nearly 10 million Americans.1

Discover More >

Plaque Psoriasis

In collaboration with UCB S.A., we are developing CIMZIA® (certolizumab pegol), a TNF-alpha inhibitor for plaque psoriasis, a chronic inflammatory skin condition that causes dry, thick, red, scaly skin. CIMZIA is the first and only PEGylated biologic treatment approved for adults with moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease.

Discover More >

Acne Vulgaris

We are developing olumacostat glasaretil (formerly DRM01), a novel small molecule designed to target sebum production following topical application to treat acne. Acne is the most common skin condition in the United States, affecting up to 50 million Americans.2

Discover More >

Atopic Dermatitis

We are developing lebrikizumab, a novel, humanized monoclonal antibody designed to specifically block the action of IL-13, a cytokine that is a central pathogenic mediator in atopic dermatitis. Atopic dermatitis is the most common and severe form of eczema, a chronic inflammatory condition. The moderate-to-severe form of atopic dermatitis affects 7 million people in the U.S. and can present as early as childhood and continue into adulthood.3

Discover More >

Helpful Resources

Many leading patient and professional organizations are doing important work for patients living with chronic skin conditions and the healthcare professionals who care for them.

Learn More >
  1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743-749.
  2. Bickers et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology. 2006;55:490-500.
  3. Silverberg & Hanifin 2013; Thomson Reuters IPD (Incidence & Prevalence Database), Accessed on August 4, 2017.